Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

L-Carnitine and Reduced Interleukin-6 Levels

Research synthesisModerate evidenceSmall effect4 studies · 3 beneficial · 1 neutral · 0 harmful

Across 4 studies, 3 reported beneficial effects of L-carnitine supplementation on reducing interleukin-6 (IL-6) levels, with a predominantly small effect size, and 1 neutral finding. One study was a large meta-analysis (n=3255) showing a statistically significant beneficial effect (p=0.001). The median study duration was 56 days (8 weeks), and most studies used doses around 2000–3000 mg/day in adult clinical populations (obese patients, critically ill patients, children on hemodialysis).

  • Effective dose range: 2000–3000 mg/day
  • Studied populations: obese patients, critically ill patients, children on hemodialysis

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). The evidence base is small (only 4 studies) — conclusions should be considered preliminary. The neutral finding came from a moderate-quality RCT in obese patients, suggesting the effect may not be universal across all populations or doses.

Generated Jul 15, 2026
Doses used in studies
  • mg/day: 1,000–3,000 (median 2,000, IQR 1,500–2,500) — 2 studies
  • mg/kg/day: 50 (median 50, IQR 50–50) — 1 study
Time to effect
Median: 8 weeks · IQR 4.5 weeks–9 weeks · Range 7 days–10 weeks — Reported in 3 of 4 studies
4 of 4 papers
Back to top